Cerebrolysin: CADASIL lifespan-use patent — US12589118B2
Stefan Winter, Herbert Mössler · 2026 · US12589118B2 · patent family 59745228
Published 2026-03-31.
Reported patent results
Reported findings
Cerebrolysin was associated with fewer deaths, while white-matter vacuolization did not improve.
CADASIL mouse experiment: 28 animals, 14 per treatment group, followed from age 12 to 18 months.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mortality | 0/14 Cerebrolysin-treated versus 5/14 (36%) vehicle-treated mice | No human participants · Age 12–18 months |
| White-matter vacuoles | 26 ± 5 with Cerebrolysin (n=14) versus 22 ± 7 with vehicle (n=8) | Mean ± SD; no significant improvement · Histological endpoint · p=0.12 |
Small animal experiment, not human longevity evidence. The absence of an effect on the pathology measure is retained alongside the survival result.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Use. The 2026 US grant concerns Cerebrolysin in CADASIL-related lifespan applications and includes genetic mouse-model support.
Animal survival and a granted use claim do not demonstrate longer human lifespan, general longevity benefit or efficacy across all stroke populations.
- Publication
- US12589118B2 ↗ · 2026-03-31
- Earliest priority / filing
- 2017-08-28 / 2018-08-28
- Original applicant / assignee
- Ever Nuero Pharma GmbH
- Indexed status
- Active · checked 2026-11-06
- Patent family
- 59745228 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation
Inventors: Stefan Winter; Herbert Mössler.
US12589118B2 · EP3449931B1 · JP7281450B2 · KR102676274B1 · CN111050780B · AU2018326339A1 · CA3073991A1 · EA202090108A1 · ES2767070T3 · HRP20200031T1 · MX2020002267A · PH12020500376A1 · PL3449931T3 · UA129400C2 · WO2019042983A1
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Animal survival and a granted use claim do not demonstrate longer human lifespan, general longevity benefit or efficacy across all stroke populations.
- Small animal experiment, not human longevity evidence. The absence of an effect on the pathology measure is retained alongside the survival result.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-59745228. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Stefan Winter, Herbert Mössler. Cerebrolysin: CADASIL lifespan-use patent — US12589118B2 US12589118B2 · patent family 59745228 2026.
Molekul research summary: https://molekul.io/research/patent-us12589118b2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry